Irbesartan: Nursing Drug Guide, Hyperkalemia & Hold Rules
Angiotensin II receptor blocker for hypertension and diabetic nephropathy: the bedside priority is hyperkalemia when potassium-raising drugs stack on the MAR, plus acute renal failure in volume-depleted or NSAID-exposed patients—and the boxed warning that irbesartan can cause fetal injury and death if pregnancy occurs. Trend BMP, ECG when ordered, blood pressure, and hold when potassium or creatinine crosses protocol limits.
Labeling states: When pregnancy is detected, discontinue irbesartan as soon as possible. Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Separately, coadministration with agents that raise serum potassium (including spironolactone and potassium supplements) may cause severe hyperkalemia. Drugs that inhibit the renin-angiotensin system may cause acute renal failure—monitor renal function and serum potassium periodically, especially in chronic kidney disease, volume depletion, or concurrent NSAID use.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, review the latest basic metabolic panel potassium and creatinine trends and scan the MAR for potassium-raising overlap—spironolactone, potassium supplements, or dual renin-angiotensin blockade. Hold irbesartan when potassium is high, creatinine jumps, pregnancy is possible, or angioedema develops; notify the team promptly when symptoms or labs cross protocol limits.
Most common brand names
Avapro is the widely recognized brand for irbesartan. Generic irbesartan is available as oral tablets in 75 mg, 150 mg, and 300 mg strengths per reviewed labeling. Verify tablet strength on every pass—75 mg, 150 mg, and 300 mg are not interchangeable without a prescriber order.
Fixed-dose combination products may pair irbesartan with hydrochlorothiazide; confirm whether combination therapy is intentional before questioning duplicate antihypertensive orders. Perform medication reconciliation when patients transition between brand and generic formulations or when home and inpatient regimens differ.
Why we give it — Indications
U.S. prescribing information lists irbesartan as an angiotensin II receptor blocker (ARB) indicated for hypertension—to lower blood pressure and reduce fatal and nonfatal cardiovascular events, primarily stroke and myocardial infarction—and for diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.
| Use | Detail |
|---|---|
| Hypertension (oral) | Initial 150 mg once daily; may increase to maximum 300 mg once daily as needed |
| Diabetic nephropathy | 300 mg once daily in type 2 diabetes with hypertension, elevated creatinine, and proteinuria (>300 mg/day) |
| Combination therapy | May be used alone or with other antihypertensive agents; may be given with or without food |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Irbesartan selectively blocks angiotensin II at the AT1 receptor, preventing vasoconstriction and aldosterone secretion. Unlike ACE inhibitors, irbesartan does not inhibit kininase II and is not associated with an increased incidence of dry cough in placebo-controlled studies (2.8% vs 2.7% with placebo per labeling). Blockade of the renin-angiotensin system reduces blood pressure but can raise serum potassium and affect renal perfusion—nurses should anticipate hyperkalemia when aldosterone effect is reduced, especially alongside potassium-sparing diuretics or supplements.
Dosing overview
Individualize to the ordered indication and renal/volume status. Labeling emphasizes correcting volume or salt depletion before full-dose initiation in at-risk patients.
Renal impairment: No dosage adjustment necessary in mild to severe renal impairment unless the patient is also volume depleted; irbesartan is not removed by hemodialysis per labeling.
Hepatic impairment: No dosage adjustment necessary in mild to moderate cirrhosis per labeling.
Pediatrics: Irbesartan did not lower blood pressure effectively in a study of patients ages 6 to 16 years at doses up to 4.5 mg/kg/day; not studied in children under 6 years.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.
Onset, peak, and duration
- Absorption: Rapid and complete; absolute bioavailability 60% to 80%; peak plasma concentrations at 1.5 to 2 hours after dosing
- Food: Does not affect bioavailability—may be given with or without food
- Half-life: Terminal elimination half-life averages 11 to 15 hours; steady state within 3 days
- Metabolism: Glucuronide conjugation and oxidation; CYP2C9 primary; no active metabolite contributes appreciably
- Excretion: About 20% in urine and remainder in feces; crosses placenta; secreted in milk of lactating rats per labeling
Before you give it — Safety check
Pretreatment checks
- Latest BMP: potassium, creatinine, BUN, sodium, glucose
- Blood pressure and orthostatic vitals—especially after first dose or in diuretic-treated patients
- Pregnancy status in patients of childbearing potential; boxed warning for fetal toxicity
- Allergies and prior angioedema with ARBs or ACE inhibitors
- MAR scan for potassium-raising drugs, NSAIDs, lithium, and dual RAS blockade
Contraindications
- Hypersensitivity to any component of irbesartan
- Do not coadminister aliskiren with irbesartan in patients with diabetes
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Agents raising potassium (spironolactone, supplements, salt substitutes) | May cause hyperkalemia, sometimes severe—monitor serum potassium | Hold and notify when potassium exceeds limits; teach patients to avoid hidden potassium sources |
| ibuprofen and other NSAIDs | May reduce antihypertensive effect; in volume-depleted or elderly patients may worsen renal function including acute renal failure | Monitor creatinine and blood pressure; question chronic NSAID use without prescriber approval |
| Lithium | Increased serum lithium and toxicity reported | Flag new lithium orders with ARBs; confirm monitoring plan with pharmacy |
| Dual RAS blockade (ACE inhibitor + ARB, or with aliskiren) | Increased hypotension, hyperkalemia, and renal impairment risk; generally avoid combined use | Verify intentional combination; trend BMP and blood pressure closely |
| furosemide and other diuretics | Volume depletion increases hypotension risk at initiation | Confirm lower 75 mg starting dose when vigorously diuretic-treated per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral only: Tablets 75 mg, 150 mg, or 300 mg. May be administered with or without food per labeling. Follow the MAR exactly for timing and strength.
- Verify tablet strength (75 vs 150 vs 300 mg) before every administration
- Pair first doses or dose increases with blood pressure measurement and orthostatic assessment when volume depletion is possible
- Reconcile home irbesartan against inpatient combination products at admission, transfer, and discharge to avoid duplicate ARB therapy
- Confirm pregnancy screening or contraception counseling when applicable before continuing therapy
Labeling warns that coadministration with drugs that raise serum potassium may result in severe hyperkalemia. Question potassium supplements or salt substitutes and potassium-based salt substitutes at home—patients may not report them unless asked directly.
Expected therapeutic response
- Gradual blood pressure reduction—effect apparent after the first dose and near full effect by about 2 weeks per labeling
- Improved blood pressure control without symptomatic hypotension or orthostatic symptoms
- In diabetic nephropathy, slowed progression of renal disease endpoints when proteinuria and hypertension are managed—monitor serum creatinine and urinalysis protein trends per orders
- Stable potassium and creatinine when potassium-raising drugs are intentionally balanced
Red flags — Stop and act
Hyperkalemia and renal dysfunction can develop insidiously when irbesartan is combined with potassium-sparing therapy, supplements, or NSAIDs—especially in chronic kidney disease.
- Potassium above prescriber or protocol hold limit, peaked T waves, widened QRS, or new muscle weakness
- Acute rise in creatinine/BUN or oliguria suggesting acute renal failure—especially with NSAIDs or dual RAS blockade
- Angioedema with facial swelling, lip or tongue swelling, or difficulty breathing—discontinue and escalate per anaphylaxis protocol
- Confirmed or suspected pregnancy—discontinue immediately per boxed warning
- Symptomatic hypotension or syncope after first dose in diuretic-treated or volume-depleted patients
- Generalized hives or anaphylactic symptoms postmarketing per labeling
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Hyperkalemia | Postmarketing and in IDNT: K >6 mEq/L in 18.6% irbesartan vs 6.0% placebo; discontinuations 2.1% vs 0.4% | Trend BMP; hold and notify for clinically significant elevations |
| Hypotension / orthostatic symptoms | Dizziness (10.2% vs 6.0% placebo in IDNT), orthostatic dizziness and orthostatic hypotension more frequent in nephropathy trial | Orthostatic vitals; fall precautions; verify 75 mg start when volume depleted |
| Renal impairment | Acute renal failure may occur in at-risk patients | Monitor creatinine; hold and notify when creatinine rises sharply |
| GI effects (hypertension trials) | Diarrhea, dyspepsia/heartburn, fatigue at ≥1% and higher than placebo | Supportive care; reassess if persistent |
| Angioedema / urticaria | Postmarketing: angioedema (face, lips, pharynx, tongue), urticaria, anaphylactic reaction | Discontinue; emergency pathway for airway compromise |
| Hepatic | Postmarketing: hepatitis, jaundice; increased LFTs reported | Notify prescriber for jaundice or marked LFT rise |
| Hypoglycemia | Postmarketing in diabetic patients | Monitor glucose in type 2 diabetes per orders |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
No human overdosage data are available in labeling. Daily doses of 900 mg for 8 weeks were well tolerated in studies. The most likely manifestations of overdosage are expected to be hypotension and tachycardia; bradycardia might also occur.
Antidote
Not specified in the reviewed prescribing information — there is no listed specific reversing agent. Treatment is supportive.
Management per labeling
- Supportive care for hypotension and tachycardia per protocol
- Irbesartan is not removed by hemodialysis
- Monitor blood pressure, heart rate, mentation, and repeat BMP as clinically indicated
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Irbesartan vs other ARBs (losartan, valsartan, olmesartan)—similar names and classes; verify exact drug and strength
- Irbesartan vs irinotecan—unrelated oncology drug; confirm indication and MAR entry
- 75 mg vs 150 mg vs 300 mg tablets—triple-check strength; diabetic nephropathy typically requires 300 mg when that is the ordered indication
- Combination products—irbesartan-hydrochlorothiazide fixed-dose tablets embed a thiazide; scan for duplicate antihypertensive ingredients
- Duplicate ARB therapy—home irbesartan plus inpatient ARB or ACE inhibitor ordering errors; reconcile the MAR at every transition
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Potassium sources | Ask explicitly about salt substitutes and OTC potassium—patients may not list them as medications |
| First-dose hypotension | Volume-depleted patients need 75 mg start and corrected volume per labeling |
| No ACE cough | Irbesartan is not associated with increased dry cough vs placebo—do not assume all RAAS drugs behave like ACE inhibitors |
| Pregnancy screening | Boxed warning—confirm contraception or pregnancy status in relevant patients before each new course |
| IDNT context | In diabetic nephropathy, hyperkalemia was common—expect closer BMP cadence at 300 mg |
| Ask pharmacy when | Dual RAS blockade, lithium overlap, unclear combination products, or refractory hyperkalemia |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Boxed fetal toxicity—discontinue when pregnancy detected; renin-angiotensin drugs can cause fetal renal failure and death |
| Volume-/salt-depleted patients | Symptomatic hypotension after initiation; start 75 mg and correct depletion per labeling |
| Chronic kidney disease / renal artery stenosis | Acute renal failure risk—monitor creatinine; consider withholding if clinically significant decrease in renal function |
| Diabetic nephropathy (type 2 diabetes) | Higher hyperkalemia rates in IDNT—18.6% with K >6 mEq/L on irbesartan; intentional 300 mg dosing |
| Elderly on diuretics/NSAIDs | Greater renal impairment risk when NSAIDs added—monitor creatinine closely |
| Lactation | No human milk data; not recommended during breastfeeding per labeling |
| Black patients (hypertension) | Antihypertensive effect somewhat less in blacks per labeling—blood pressure still requires monitoring |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum potassium and renal function (creatinine, BUN)—periodically per labeling, especially with potassium-raising drugs
- Blood pressure and orthostatic vitals after initiation, dose changes, or when diuretics are concurrent
- ECG or telemetry when hyperkalemia is suspected or potassium is borderline high
- Proteinuria and creatinine trends in diabetic nephropathy
- Signs of angioedema, dizziness, or hypertension symptoms recurrence
Document
- Dose, time, tablet strength, indication, and blood pressure response
- Latest BMP values and any hold parameters triggered
- Pregnancy status or contraception counseling when applicable
- Patient teaching on salt substitutes, potassium supplements, and when to report weakness or swelling
Patient teaching
- Report muscle weakness, palpitations, dizziness, swelling of face or lips, or decreased urination promptly
- Do not use potassium-based salt substitutes or start potassium supplements unless prescriber directs—risk of dangerous hyperkalemia with irbesartan
- Do not take OTC NSAIDs without asking your prescriber—they can raise blood pressure and harm kidneys
- Use effective contraception and notify your care team immediately if pregnancy is possible—this medicine can harm an unborn baby
- Rise slowly from sitting or lying down to reduce orthostatic dizziness
- Keep follow-up appointments for blood tests that monitor potassium and kidney function
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known irbesartan allergy, angioedema, or anaphylaxis with ARBs
- Potassium above institutional hold parameters or ECG changes consistent with hyperkalemia
- Confirmed or suspected pregnancy—discontinue per boxed warning
- Symptomatic hypotension, syncope, or acute mental status change suggesting hypoperfusion
- Marked creatinine/BUN rise or oliguria suggesting acute renal failure
- Scheduled dose when dangerous potassium-raising overlap (salt substitute, spironolactone, supplements) has not been clarified
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Irbesartan is a cornerstone ARB for hypertension and diabetic nephropathy—and a common source of preventable hyperkalemia when nurses treat it as routine without trending potassium and scanning for hidden potassium sources on the MAR.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right BMP within acceptable timeframe
- Verify tablet strength (75 vs 150 vs 300 mg) matches the MAR and indication
- Scan for spironolactone, potassium supplements, NSAIDs, lithium, and dual RAS agents
- Confirm pregnancy status when applicable before administration
2. High-alert and safety badge
Not on all institutional high-alert lists, but boxed fetal toxicity and hyperkalemia risk require BMP discipline, pregnancy screening, and hold rules—especially at 300 mg in diabetic nephropathyLabeling emphasizes monitoring renal function and serum potassium during therapy.
3. Clinical workflow: hold and question rules
- If potassium is rising across shifts, hold the next dose and page the team before giving another ARB dose
- If creatinine jumps while NSAIDs are used PRN, clarify whether irbesartan and NSAID overlap is safe
- Question 300 mg orders in volume-depleted patients when 75 mg initiation is indicated per labeling
4. Critical teach-back questions
- “What should you avoid at the dinner table while taking this blood pressure medicine?” (Patient should name potassium-based salt substitutes and unauthorized potassium pills.)
- “What symptoms mean you should call the team right away?” (Patient should name weakness, palpitations, facial swelling, or decreased urination.)
5. Care coordination
Pharmacist: Combination product review, potassium-raising interaction screening, lithium overlap, and hyperkalemia management protocols
Prescriber: Notify for hyperkalemia with ECG changes, acute creatinine rise, angioedema, symptomatic hypotension, or pregnancy
🧠 Quick mental checklist
- What is the latest potassium—and is spironolactone or a salt substitute on the MAR?
- Is this a 75, 150, or 300 mg tablet—and does volume status support that dose?
- Has creatinine risen since irbesartan started or since NSAID use?
- Could this patient be pregnant?
- Did I teach the patient what weakness, palpitations, and facial swelling mean?
Irbesartan NCLEX practice questions
Practice NCLEX-style clinical judgment practice for irbesartan using a tabbed diabetic nephropathy case (MAR, labs, vitals, nursing notes), then priority action, cue recognition SATA, potassium trend SATA, matrix urgency sorting, volume-depletion dose judgment, and overdose cloze—with explicit evaluate outcomes items after hyperkalemia intervention.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Irbesartan 300 mg PO daily — due 0900
- Spironolactone 25 mg PO daily — given 0700
- Metformin 1000 mg PO BID — given 0700
- Ibuprofen 400 mg PO q8h PRN — last dose yesterday for knee pain
- Patient reports using potassium-based salt substitute at meals (not on MAR until today)
- Admission K+ 4.3 mEq/L; yesterday 5.2; today 5.9 mEq/L (BMP 0800)
- Creatinine 1.4 → 2.1 mg/dL over 72 h; BUN 22 → 36 mg/dL
- Glucose 142 mg/dL; eGFR trend declining per lab report
- BP 128/76 mmHg; HR 88/min; RR 16/min; SpO2 97% on room air
- Orthostatics: lying BP 130/78; standing BP 118/70 with reported lightheadedness
- ECG: peaked T waves in precordial leads since 0830
- 58-year-old with type 2 diabetes, hypertension, and diabetic nephropathy; home irbesartan 300 mg continued on admission
- 0840: reports generalized weakness and palpitations; denies chest pain
- 0845: daughter brought potassium-based salt substitute from home—patient started using it two days ago
- 0900: irbesartan 300 mg due; nurse reviewing case tabs before administration
Answer key & rationale
Frequently asked questions
What should I check before giving irbesartan?
Review the latest basic metabolic panel (especially potassium, creatinine, and BUN), confirm blood pressure and orthostatic symptoms, verify pregnancy status in patients of childbearing potential, scan the MAR for potassium-raising drugs (spironolactone, potassium supplements, salt substitutes), NSAIDs, lithium, and dual renin-angiotensin system blockade, and match tablet strength (75, 150, or 300 mg) to the order.
When should nurses hold irbesartan?
Hold and contact the prescriber or pharmacist when potassium exceeds protocol limits or ECG changes suggest hyperkalemia, creatinine rises sharply or acute renal failure is suspected, symptomatic hypotension occurs—especially in volume-depleted patients—pregnancy is confirmed or suspected, angioedema or anaphylaxis develops, or known hypersensitivity exists. Do not restart until the team clarifies the plan.
Why is hyperkalemia common with irbesartan in diabetic nephropathy?
Irbesartan blocks angiotensin II and can raise serum potassium, especially with concurrent potassium-sparing diuretics or supplements. In the Irbesartan Diabetic Nephropathy Trial (IDNT), potassium greater than 6 mEq/L occurred in 18.6% of irbesartan-treated patients versus 6.0% on placebo. Nurses should trend BMP after initiation or dose changes and hold therapy when hyperkalemia is clinically significant.
Can irbesartan be used in pregnancy?
No. Labeling carries a boxed warning for fetal toxicity: when pregnancy is detected, discontinue irbesartan as soon as possible. Drugs acting on the renin-angiotensin system can cause fetal injury and death, including oligohydramnios, renal failure, and skull hypoplasia. Use effective contraception counseling and immediately notify the prescriber if pregnancy is possible.
Is there an antidote for irbesartan overdose?
No specific antidote is listed in the reviewed prescribing information. Overdosage most likely causes hypotension and tachycardia; bradycardia might also occur. Irbesartan is not removed by hemodialysis. Treatment is supportive—manage blood pressure and heart rate per protocol. Contact local poison control or medical toxicology services per facility guidance for significant overdose.
References
- U.S. National Library of Medicine. IRBESARTAN tablet — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9adacfa2-2814-4deb-9e34-c3b3c8dcd41a
- Joint Formulary Committee. Irbesartan monograph. BNF (NICE).https://bnf.nice.org.uk/drugs/irbesartan/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.